Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Maelle GiveletVirginie FirlejBruno LassalleAnne Sophie GilleClementine LapoujadeIsabelle HoltzmanAmandine JarystaFarahd HaghighiradFlorent DumontSébastien JacquesFranck LetourneurFrançoise PflumioIsabelle AllemandCatherine PatratNicolas ThiounnJean Philippe WolfLydia RiouVirginie Barraud-LangePierre Fouchet
• Organismes : Stabilité génétique, cellules souches et radiations Institut Cochin Stabilité génétique, cellules souches et radiations Institut Cochin Stabilité génétique, cellules souches et radiations Stabilité génétique, cellules souches et radiations Institut Cochin Stabilité génétique, cellules souches et radiations Institut Cochin Stabilité génétique, cellules souches et radiations UFR Médecine [Santé] - Université Paris Cité Ingénierie et Plateformes au Service de l'Innovation Thérapeutique Institut Cochin Institut Cochin Plateforme de genomique Stabilité génétique, cellules souches et radiations Stabilité génétique, cellules souches et radiations Hôpital Cochin [AP-HP] UFR Médecine [Santé] - Université Paris Cité Hôpital Européen Georges Pompidou [APHP] Université Paris Descartes - Paris 5 Hôpital Cochin [AP-HP] UFR Médecine [Santé] - Université Paris Cité Stabilité génétique, cellules souches et radiations Hôpital Cochin [AP-HP] UFR Médecine [Santé] - Université Paris Cité Stabilité génétique, cellules souches et radiations
• Publié dans Stem Cell Reports le 01/11/2020

---

Résumé : Male infertility is responsible for approximately half of all cases of reproductive issues. Spermatogenesis originates in a small pool of spermatogonial stem cells (SSCs), which are of interest for therapy of infertility but remain not well defined in humans. Using multiparametric analysis of the side population (SP) phenotype and the α-6 integrin, THY1, and β-2 microglobulin cell markers, we identified a population of human primitive undifferentiated spermatogonia with the phenotype β-2 microglobulin (β-2M)-SPα-6+THY1+, which is highly enriched in stem cells. By analyzing the expression signatures of this SSC-enriched population along with other germinal progenitors, we established an exhaustive transcriptome of human spermatogenesis. Transcriptome profiling of the human β-2M-SPα-6+THY1+ population and comparison with the profile of mouse undifferentiated spermatogonia provide insights into the molecular networks and key transcriptional regulators regulating human SSCs, including the basic-helix-loop-helix (bHLH) transcriptional repressor HES1, which we show to be implicated in maintenance of SSCs in vitro.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Laurence SchenoneCaroline HouillierMarie-Laure TanguySylvain ChoquetKossi AgbetiafaHervé GhesquièresGandhi DamajAnna SchmittKrimo BouabdallahGuido AhleRemy GressinJérôme CornillonRoch HouotJean-Pierre MarolleauLuc-Matthieu ForneckerOlivier ChinotFrédéric PeyradeReda BouabdallahCécile Moluçon-ChabrotEmmanuel GyanAdrien ChauchetOlivier CasasnovasLucie ObericVincent DelwailJulie AbrahamVirginie RolandAgathe Waultier-RascalouLise WillemsFranck MorschhauserMichel FabbroRenata UrsuCatherine ThieblemontFabrice JardinAdrian TempesculDenis MalaiseValérie TouitouLucia NichelliMagali Le Garff-TavernierAurélie PlessierPhilippe BourgetCaroline BonmatiSophie Wantz-MézièresQuentin GiordanVéronique DorvauxCyril CharronWaliyde JabeurKhê Hoang-XuanLuc TaillandierCarole Soussain
• Organismes : Service d'Hématologie [CHRU Nancy] Institut du Cerveau = Paris Brain Institute Institut Gustave Roussy Service de biostatistique et d'épidémiologie CHU Pitié-Salpêtrière [AP-HP] Département d'hématologie, Institut Curie, Site Saint-Cloud Centre Hospitalier Lyon Sud [CHU - HCL] Immuno-Biologie des Lymphomes [CIRI] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Institut Bergonié [Bordeaux] Centre Hospitalier Universitaire de Bordeaux Service de Neurologie [Hôpitaux Civils de Colmar] Centre Hospitalier Universitaire [CHU Grenoble] Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne [CHU Saint-Etienne] Microenvironment, Cell Differentiation, Immunology and Cancer Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer CHU Amiens-Picardie HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 Centre Hospitalier Universitaire [Strasbourg] Institut de neurophysiopathologie Hôpital de la Timone [CHU - APHM] Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] Institut Paoli-Calmettes Service Hématologie Biologique [CHU Clermont-Ferrand] Hôpital Bretonneau Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Institut Universitaire du Cancer de Toulouse - Oncopole CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Hôpital Dupuytren [CHU Limoges] Centre Hospitalier Saint Jean de Perpignan Hôpital Universitaire Carémeau [Nîmes] Hôpital Cochin [AP-HP] Centre Hospitalier Régional Universitaire [CHU Lille] Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 Institut régional de Cancérologie de Montpellier Hopital Saint-Louis [AP-HP] Hopital Saint-Louis [AP-HP] NF-kappaB, Différenciation et Cancer Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre Hospitalier Régional Universitaire de Brest Département d'Oncologie Chirurgicale [Institut Curie] Laboratoire d'Imagerie Translationnelle en Oncologie CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Hôpital Beaujon [AP-HP] Hôpital Necker - Enfants Malades [AP-HP] Centre Hospitalier Régional Universitaire de Nancy Biology, genetics and statistics Institut Élie Cartan de Lorraine Hôpital de Mercy Centre hospitalier régional de Metz-Thionville Hôpital Ambroise Paré [AP-HP] Maladies neurodéveloppementales et neurovasculaires Institut du Cerveau = Paris Brain Institute CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche en Automatique de Nancy Centre Hospitalier Régional Universitaire de Nancy Institut Curie - Saint Cloud Immunité et cancer
• Publié dans Bone Marrow Transplantation le 01/11/2020

---

Résumé : We analysed the therapeutic outcomes of all consecutive patients with primary central nervous system lymphoma (PCNSL) registered in the prospective French database for PCNSL and treated with intensive chemotherapy (IC) followed by autologous stem cell transplantation (IC-ASCT) between 2011 and November 2019 (271 patients recruited, 266 analysed). In addition, treatment-related complications of thiotepa-based IC-ASCT were analysed from the source files of 85 patients from 3 centers. Patients had received IC-ASCT either in first-line treatment (n\,=\,147) or at relapse (n\,=\,119). The median age at IC-ASCT was 57 years (range: 22-74). IC consisted of thiotepa-BCNU (n\,=\,64), thiotepa-busulfan (n\,=\,24), BCNU-etoposide-cytarabine-melphalan (BEAM, n\,=\,36) and thiotepa-busulfan-cyclophosphamide (n\,=\,142). In multivariate analysis, BEAM and ASCT beyond the first relapse were adverse prognostic factors for relapse risk. The risk of treatment-related mortality was higher for ASCT performed beyond the first relapse and seemed higher for thiotepa-busulfan-cyclophosphamide. Thiotepa-BCNU tends to result in a higher relapse rate than thiotepa-busulfan-cyclophosphamide and thiotepa-busulfan. This study confirms the role of IC-ASCT in first-line treatment and at first-relapse PCNSL (5-year overall survival rates of 80 and 50%, respectively). The benefit/risk ratio of thiotepa-busulfan/thiotepa-busulfan-cyclophosphamide-ASCT could be improved by considering ASCT earlier in the course of the disease and dose adjustment of the IC.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Olivier HermineXavier MarietteRaphaël PorcherFelix DjossouYann NguyenJean-Benoît ArletLaurent SavaleJean-Luc DiehlSophie Georgin-LavialleJacques CadranelGilles PialouxKarine LacombeArsène MékinianHélène GrosXavier LescureJade GhosnElisabeth CoupezKevin GrapinChristophe RappMarc MichelAnne Lise LecapitaineJean Marie MichotNathalie Costedoat-ChalumeauLiem Binh Luong NguyenLuca SemeranoFrançois RaffiClaire AguillarClaire RouzaudJacques-Eric GottenbergYves HansmannBoris BienvenuJonathan LondonFranklin Samou FantchouFelix AckermannAntoine GrosAlexandre MorelNicolas GambierDamien SèneBruno MégarbaneÉlie AzoulaySerge BureauMaxime DougadosJoseph EmmerichMuriel FartoukhBertrand GuidetMarc HumbertMathieu MahevasFrédéric PèneFrédéric SchlemmerValérie PourcherAnnick TibiGabriel BaronElodie PerrodeauStéphanie BaronPhilippe Gabriel StegYazdan YazdapanahTabassome SimonMatthieu Resche-RigonPierre-Louis TharauxPhilippe Ravaud
• Organismes : Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Université Paris-Saclay Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Hôpital Hôtel-Dieu [Paris] Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 Unité des Maladies Infectieuses et Tropicales Hôpital Beaujon [AP-HP] Université Paris Cité Université Paris Cité Hôpital Européen Georges Pompidou [APHP] Hypertension pulmonaire : physiopathologie et innovation thérapeutique Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Européen Georges Pompidou [APHP] Université Paris Cité CHU Tenon [AP-HP] Université Sorbonne Paris Cité CHU Tenon [AP-HP] Université Sorbonne Paris Cité CHU Tenon [AP-HP] Université Sorbonne Paris Cité Université Sorbonne Paris Nord CHU Saint-Antoine [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Université Sorbonne Paris Nord Hôpital Robert Ballanger [Aulnay-sous-Bois] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution CHU Gabriel Montpied [Clermont-Ferrand] CHU Gabriel Montpied [Clermont-Ferrand] Hôpital Américain de Paris Hôpital Henri Mondor Université Paris-Est Créteil Val-de-Marne - Paris 12 Centre Hospitalier Compiègne-Noyon Institut Gustave Roussy Université Paris-Saclay Département d'hématologie [Gustave Roussy] Hôpital Cochin [AP-HP] Sorbonne Université Hôpital Cochin [AP-HP] CIC Cochin Pasteur Hôpital Avicenne [AP-HP] Université Sorbonne Paris Nord Hôtel-Dieu de Nantes Centre d’Investigation Clinique de Nantes Hôpital Necker - Enfants Malades [AP-HP] Université Paris Descartes - Paris 5 Hôpital Necker - Enfants Malades [AP-HP] Centre hospitalier Saint-Joseph [Paris] Hôpitaux Universitaires de Strasbourg Université de Strasbourg Hôpitaux Universitaires de Strasbourg Université de Strasbourg Hôpital Saint-Joseph [Marseille] Groupe Hospitalier Diaconesses Croix Saint-Simon Centre Hospitalier de l'Ouest Guyanais Franck Joly [Saint-Laurent-du-Maroni, Guyane Française] Hôpital Foch [Suresnes] Centre Hospitalier de Versailles André Mignot Hôpital privé d’Antony Hôpital Delafontaine Hôpital Lariboisière-Fernand-Widal [APHP] Université Paris Diderot - Paris 7 Hôpital Lariboisière-Fernand-Widal [APHP] Optimisation thérapeutique en Neuropsychopharmacologie Université Paris Diderot - Paris 7 Hopital Saint-Louis [AP-HP] Université Paris Diderot - Paris 7 Hopital Saint-Louis [AP-HP] Université Paris-Est Hôpital Cochin [AP-HP] Université Paris-Est Centre hospitalier Saint-Joseph [Paris] Université Paris Descartes - Paris 5 CHU Tenon [AP-HP] Université Sorbonne Paris Cité CHU Saint-Antoine [AP-HP] Université Sorbonne Paris Cité Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital Européen Georges Pompidou [APHP] Université Paris-Saclay Hôpital Henri Mondor Université Paris-Est Créteil Val-de-Marne - Paris 12 Hôpital Cochin [AP-HP] Université Paris Descartes - Paris 5 Hôpital Henri Mondor Université Paris-Est Créteil Val-de-Marne - Paris 12 CHU Pitié-Salpêtrière [AP-HP] Université Sorbonne Paris Cité Agence Générale des Equipements et Produits de Santé [Paris] Hôpital Hôtel-Dieu [Paris] Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Hôpital Hôtel-Dieu [Paris] Hôpital Européen Georges Pompidou [APHP] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université Paris Diderot - Paris 7 AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université Paris Cité CHU Saint-Antoine [AP-HP] Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Hopital Saint-Louis [AP-HP] Paris-Centre de Recherche Cardiovasculaire Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Hôpital Hôtel-Dieu [Paris]
• Publié dans EClinicalMedicine le 01/11/2020

---

Résumé : Background: In moderate-to-severe COVID-19 pneumonia, dexamethasone (DEX) and tocilizumab (TCZ) reduce the occurrence of death and ventilatory support. We investigated the efficacy and safety of DEX+TCZ in an open randomized clinical trial. Methods: From July 24, 2020, through May 18, 2021, patients with moderate-to-severe COVID-19 pneumonia requiring oxygen (>3 L/min) were randomly assigned to receive DEX (10 mg/d 5 days tapering up to 10 days) alone or combined with TCZ (8 mg/kg IV) at day 1, possibly repeated with a fixed dose of 400 mg i.v. at day 3. The primary outcome was time from randomization to mechanical ventilation support or death up to day 14, analysed on an intent-to-treat basis using a Bayesian approach. ClinicalTrials.gov number, NCT04476979. Findings: A total of 453 patients were randomized, 3 withdrew consent, 450 were analysed, of whom 226 and 224 patients were assigned to receive DEX or TCZ+DEX, respectively. At day 14, mechanical ventilation or death occurred in 32/226 (14%) and 27/224 (12%) in the DEX and TCZ+DEX arms, respectively (hazard ratio [HR] 0·85, 90% credible interval [CrI] 0·55 to 1·31). At day 14, the World health Organization (WHO) clinical progression scale (CPS) was significantly improved in the TCZ+DEX arm (OR 0·69, 95% CrI, 0·49 to 0.97). At day 28, the cumulative incidence of oxygen supply independency was 82% in the TCZ+DEX arms and 72% in the DEX arm (HR 1·36, 95% CI 1·11 to 1·67). On day 90, 24 deaths (11%) were observed in the DEX arm and 18 (8%) in the TCZ+DEX arm (HR 0·77, 95% CI 0·42-1·41). Serious adverse events were observed in 25% and 21% in DEX and TCZ+DEX arms, respectively. Interpretation: Mechanical ventilation need and mortality were not improved with TCZ+DEX compared with DEX alone. The safety of both treatments was similar. However, given the wide confidence intervals for the estimate of effect, definitive interpretation cannot be drawn. Funding: Programme Hospitalier de Recherche Clinique [PHRC COVID-19-20-0151, PHRC COVID-19-20-0029], Fondation de l'Assistance Publique - Hôpitaux de Paris (Alliance Tous Unis Contre le Virus) and from Fédération pour la Recherche Médicale" (FRM). Tocilizumab was provided by Roche.

---

Fichiers liés : PIIS258953702200092X.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Jean‐philippe DesillesMialitiana Solo NomenjanaharyArturo ConsoliVéronique OllivierDorothée FailleMarie‐charlotte BourrienneMylène HamdaniSebastien DupontLucas Di MeglioSimon EscalardBenjamin MaierRaphael BlancMichel PiotinBertrand LapergueNadine AjzenbergMarc VasseMikael MazighiBenoit Ho-Tin-NoéJean‐philippe DésillesMikael MazighiMichel PiotinRaphael BlancHocine RedjemStanislas SmajdaPierre SenersSimon EscalardFrancois DelvoyeBenjamin MaierSolene HebertMalek Ben MaachaMylene HamdaniCandice SabbenMichael ObadiaCatherine DeschildreBertrand LapergueArturo ConsoliGeorges RodeschFederico MariaOkuzan CoskunDelphine LopezRomain BourcierLili DetrazHubert DesalMonica RoyDelphine ClavierGaultier MarnatFlorent GarielLudovic LucasIgor SibonFrancois EugeneStéphane VannierJean‐christophe FerreAnthony LebrasHélène RaoultChristophe PayaJean‐yves GauvritSébastien RichardBenjamin GoryCharlotte BarbierDenis VivienEmmanuel TouzeMaxime GaubertiGaetane BlaizotHéloïse IferganDenis HerbreteauRichard BibiKevin JanotVladimir CharronGrégoire Boulouis
• Organismes : Laboratoire de Recherche Vasculaire Translationnelle Laboratoire de Recherche Vasculaire Translationnelle Laboratoire de Recherche Vasculaire Translationnelle Hémostase, Inflammation, Thrombose
• Publié dans Journal of Thrombosis and Haemostasis le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Guillaume DomainCecile ChouquetPatricia RéantVanina BongardTheo VedisAnne RollinFranck MandelHubert DelasnerieQuentin Voglimacci-StephanopoliPierre MondolyMaxime BeneytoEve CariouPauline FournierClément DelmasMichel GalinierDidier CarriéStéphane LafitteOlivier LairezJean FerrièresHubert CochetPhilippe Maury
• Organismes : Service Cardiologie [CHU Toulouse] Institut de Mathématiques de Toulouse UMR5219 Département de cardiologie Service Cardiologie [CHU Toulouse] Equipe AGING (CERPOP) Institut de Mathématiques de Toulouse UMR5219 Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Département de cardiologie Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Equipe AGING (CERPOP) Département de cardiologie Service Cardiologie [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires
• Publié dans European Heart Journal - Cardiovascular Imaging le 25/10/2020

---

Résumé : Aims: Hypertrophic cardiomyopathy (HCM) may be associated with very narrow QRS, while left ventricular hypertrophy (LVH) may increase QRS duration. We investigated the relationships between QRS duration and LV mass (LVM) in subtypes of abnormal LV wall thickness. Methods and results: Automated measurement of LVM on MRI was correlated to automated measurement of QRS duration on ECG in HCM, left ventricular non compaction (LVNC), left ventricular hypertrophy (LVH), and controls with healthy hearts. Uni and multivariate analyses were performed between groups including explanatory variables expected to influence LVM and QRS duration. The relationships between QRS duration and LVM were further studied within each group. Two hundred and twenty-one HCM, 28 LVNC, 16 LVH, and 40 controls were retrospectively included. Mean QRS duration was 92 ms for HCM, 104 for LVNC, 110 for LVH, and 92 for controls (P < 0.01). Mean LVM was 100, 90, 108, and 68 g/m2 (P < 0.01). QRS duration, LVM, hypertension, maximal wall thickness, and late gadolinium enhancement were significantly linked to HCM in multivariate analysis (w/wo bundle branch block). An independent negative correlation was found between LVM and QRS duration in the HCM group, while the relationship was reverse in LVNC, LVH, and controls. Conclusion: QRS duration increases with LVM in LVNC, LVH, or in healthy hearts, while reverse relationship is present in HCM. These relationships were independent from other parameters. These results warrant additional investigations for refining diagnosis criteria for HCM in the future.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Bertrand GuidetChristian JungHans FlaattenJesper FjølnerAntonio ArtigasBernardo Bollen PintoJoerg SchefoldMichael BeilSviri SigalPeter Vernon van HeerdenWojciech SzczeklikMichael JoannidisSandra OeyenEumorfia KondiliBrian MarshFinn AndersenRui MorenoMaurizio CecconiSusannah LeaverDylan de LangeAriane BoumendilPhilipp EllerMichael JoannidisDieter MesottenPascal ReperSandra OeyenWalter SwinnenHelene BrixJens BrushoejMaja VillefranceHelene Korvenius NedergaardAnders Thais BjerregaardIda Riise BallebyKasper AndersenMaria Aagaard HansenStine UhrenholtHelle BundgaardJesper FjølnerAliae HusseinRehab SalahYasmin Khairy Nasr Eldin Mohamed AliKyrillos WassimYumna ElgazzarSamar TharwatAhmed AzzamAyman Abdelmawgoad HabibHazem Maarouf AbosheaishaaMohammed AzabSusannah LeaverArnaud GalboisTomas UrbinaCyril CharronEmmanuel GuerotGuillaume BeschJean-Philippe RigaudJulien MaizelMichel DjibréPhilippe BurtinPierre GarconSaad NseirXavier ValetteNica AlexandruNathalie MarinMarie VaissiereGaëtan PlantefeveThierry VanderlindenIgor JurcisinBuno MegarbaneAnais CaillardArnaud ValentMarc GarnierSebastien BessetJohanna OzielJean-Herlé RaphalenStéphane DaugerGuillaume DumasBruno GoncalvesGaël PitonEberhard BarthUlrich GoebelEberhard BarthAnselm KunsteinMichael SchusterMartin WelteMatthias LutzPatrick MeybohmStephan SteinerTudor PoernerHendrik HaakeStefan SchallerStefan SchallerStefan SchallerDetlef Kindgen-MillesChristian MeyerMuhammed KurtKarl Friedrich KuhnWinfried RanderathJakob WollbornZouhir DindaneHans-Joachim KabitzIngo VoigtGonxhe ShalaAndreas FaltlhauserNikoletta RovinaZoi AidoniEvangelia ChrisanthopoulouAntonios PapadogoulasMohan GurjarAta MahmoodpoorAbdullah Khudhur AhmedBrian MarshAhmed ElsakaSigal SviriVittoria ComelliniAhmed RabhaHazem AhmedSilvio Namendys-SilvaAbdelilah GhannamMartijn GroenendijkMarieke ZegersDylan de LangeAlexander Daniel CornetMirjam EversLenneke HaasTom DormansWillem DieperinkLuis RomundstadBritt SjøbøFinn AndersenHans Frank StrietzelTheresa OlasveengenMichael HahnMiroslaw CzuczwarRyszard GawdaJakub KlimkiewiczMaria de Lurdes Campos SantosAndré GordinhoHenrique SantosRui AssisAna Isabel Pinho OliveiraMohamed Raafat BadawyDavid Perez-TorresGemma GomàMercedes Ibarz VillamayorAngela Prado MiraPatricia Jimeno CuberoSusana Arias RiveraTeresa TomasaDavid IglesiasEric Mayor VázquezCesar AldecoaAida Fernández FerreiraBegoña Zalba-EtayoIsabel Canas-PerezLuis Tamayo-LomasCristina Diaz-RodriguezSusana SanchoJesús PriegoEnas AbualqumbozMomin Majed Yousuf HillesMahmoud SalehNawfel Ben-HamoudaAndrea RobertiAlexander DullenkopfYvan FleuryBernardo Bollen PintoJoerg SchefoldMohammed Al-Sadaw
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Optimisation thérapeutique en Neuropsychopharmacologie
• Publié dans Intensive Care Medicine le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Adrien JosephMartin EloitÉlie AzoulayGilles KaplanskiFrançois ProvotClaire PresneAlain WynckelSteven GrangéÉric RondeauFrédéric PèneYahsou DelmasAlexandre LautretteChristelle BarbetChristiane MoussonJean‐philippe CoindrePierre PerezMatthieu JammeJean‐françois AugustoPascale PoullinFrédéric JacobsKhalil El KarouiCécile VigneauMarc UlrichTarik KanouniMoglie Le QuintrecMohamed HamidouSimon VilleAnne Charvet‐rumplerMario Ojeda‐uribePascal GodmerVéronique Fremeaux‐bacchiAgnès VeyradierJean‐michel HalimiPaul Coppo
• Organismes : Centre de Recherche des Cordeliers Hopital Saint-Louis [AP-HP] Centre Hospitalier Régional Universitaire de Tours Hopital Saint-Louis [AP-HP] Hôpital de la Conception [CHU - APHM] Hôpital Albert Calmette CHU Amiens-Picardie Hôpital Maison Blanche Hôpital Charles Nicolle [Rouen] CHU Tenon [AP-HP] Hôpital Cochin [AP-HP] Service de Néphrologie-transplantation-dialyse [Bordeaux] CHU Gabriel Montpied [Clermont-Ferrand] Hôpital Bretonneau Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Le Mans (CH Le Mans) Centre Hospitalier Régional Universitaire de Nancy Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Centre Hospitalier Universitaire de Toulouse Hôpital de la Conception [CHU - APHM] AP-HP - Hôpital Antoine Béclère [Clamart] Hôpital Henri Mondor École des Hautes Études en Santé Publique Institut de recherche en santé, environnement et travail Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre hospitalier [Valenciennes, Nord] CHU Montpellier = Montpellier University Hospital Centre Hospitalier Régional Universitaire [Montpellier] Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Emile Muller [Mulhouse] Centre hospitalier Bretagne Atlantique (Morbihan) Hôpital Européen Georges Pompidou [APHP] Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] Hôpital Bretonneau CHU Saint-Antoine [AP-HP]
• Publié dans Research and Practice in Thrombosis and Haemostasis le 02/07/2020

---

Résumé : BACKGROUND: The prevalence, prognostic role, and diagnostic value of blood pressure in immune-mediated thrombotic thrombocytopenic purpura (iTTP) and other thrombotic microangiopathies (TMAs) remain unclear. METHODS: Using a national cohort of iTTP (n = 368), Shigatoxin-induced hemolytic uremic syndrome (n = 86), atypical hemolytic uremic syndrome (n = 84), and hypertension-related thrombotic microangiopathy (n = 25), we sought to compare the cohort’s blood pressure profile to assess its impact on prognosis and diagnostic performances. RESULTS: Patients with iTTP had lower blood pressure than patients with other TMAs, systolic (130 [interquartile range (IQR) 118-143] vs 161 [IQR 142-180] mmHg) and diastolic (76 [IQR 69-83] vs 92 [IQR 79-105] mmHg, both p < 0.001). The best threshold for iTTP diagnosis corresponded to a systolic blood pressure <150 mmHg. iTTP patients presenting with hypertension had a significantly poorer survival (hazard ratio 1.80, 95% confidence interval 1.07-3.04), and this effect remained significant after multivariable adjustment (hazard ratio = 1.14, 95% confidence interval 1.00-1.30). Addition of a blood pressure criterion modestly improved the French clinical score to predict a severe A disintegrin and metalloprotease with thrombospondin type 1 deficiency in patients with an intermediate score (i.e., either platelet count <30 × 10(9)/L or serum creatinine <200 µM). CONCLUSIONS: Elevated blood pressure at admission affects the prognosis of iTTP patients and may help discriminate them from other TMA patients. Particular attention should be paid to blood pressure and its management in these patients.

---

Fichiers liés : 1-s2.0-S2475037922012080-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Aurélie BichotSana RaoucheCraig B FauldsValérie MechinNicolas BernetJean-Philippe DelgenèsDiana Garcia-Bernet
• Organismes : Laboratoire de Biotechnologie de l'Environnement [Narbonne] Biodiversité et Biotechnologie Fongiques Biodiversité et Biotechnologie Fongiques Institut Jean-Pierre Bourgin - Sciences du végétal Laboratoire de Biotechnologie de l'Environnement [Narbonne] Laboratoire de Biotechnologie de l'Environnement [Narbonne] Laboratoire de Biotechnologie de l'Environnement [Narbonne]
• Publié dans Biochemical Engineering Journal le 28/10/2020

---

Résumé : Biomass recalcitrance is one of the main bottlenecks in lignocellulosic biorefinery deployment. Physico-chemical pretreatments and enzymatic hydrolysis are two procedures that can be combined to overcome this recalcitrance. In this study microwave pretreatment has been selected for its relevant conditions that allow for biomass recalcitrance to be reduced, along with the maintenance of a low consumption of energy and reactants. A xylanolytic enzymatic cocktail, Rovabio® Advance, was investigated for its ability to hydrolyze maize stalks and Miscanthus leaves after pressurized, chemical-free microwave pretreatment. This combination was implemented to increase the breakage of ester bonds and thus facilitate the release of p-hydroxycinnamic acids. This study demonstrates how, in comparison with Miscanthus, both pretreatments are more effective in releasing p-hydroxycinnamic acids from maize stalks, due to their lower parietal content. The successive free-chemical process seems to be particularly promising on maize stalks, since it led to a ferulic acid release yield of 18.2%, compared to 5.5% for microwave pretreatment only or 7.6% when performing enzymatic hydrolysis without a microwave pretreatment step.

---

Fichiers liés : S1369703X22001036.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Sarra SmatiArnaud PolizziAnne FougeratSandrine Ellero-SimatosYuna BlumYannick LippiMarion RégnierAlexia LaroyenneMarine HuilletMuhammad ArifCheng ZhangFrédéric LasserreAlain MarrotTalal Al SaatiJinghong WanCaroline SommerClaire NayliesAurélie BatutCéline LukowiczTiffany FougerayBlandine TramuntPatricia DubotLorraine SmithJustine Bertrand-MichelNathalie HennuyerJean-Philippe PradereBart StaelsRemy BurcelinFrançoise LenfantJean-François ArnalThierry LevadeLaurence Gamet-PayrastreSandrine LagarrigueNicolas LoiseauSophie LotersztajnCatherine PosticWalter WahliChristophe BureauMaeva GuillaumeAdil MardinogluAlexandra MontagnerPierre GourdyHervé Guillou
• Organismes : ToxAlim Institut des Maladies Métaboliques et Casdiovasculaires Toxicologie Intégrative & Métabolisme Toxicologie Intégrative & Métabolisme Toxicologie Intégrative & Métabolisme Institut de Génétique et Développement de Rennes Ligue Nationale Contre le Cancer Transcriptomic impact of Xenobiotics ToxAlim ToxAlim Toxicologie Intégrative & Métabolisme KTH Royal Institute of Technology [Stockholm] KTH Royal Institute of Technology [Stockholm] Toxicologie Intégrative & Métabolisme ToxAlim ANEXPLO Centre de recherche sur l'Inflammation Plateforme Ezop Transcriptomic impact of Xenobiotics Institut des Maladies Métaboliques et Casdiovasculaires ToxAlim Toxicologie Intégrative & Métabolisme Institut des Maladies Métaboliques et Casdiovasculaires Centre de Recherches en Cancérologie de Toulouse Toxicologie Intégrative & Métabolisme Institut des Maladies Métaboliques et Casdiovasculaires Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Institut des Maladies Métaboliques et Casdiovasculaires Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Centre de Recherches en Cancérologie de Toulouse Toxicologie Intégrative & Métabolisme Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] Toxicologie Intégrative & Métabolisme Centre de recherche sur l'Inflammation Institut Cochin ToxAlim Lee Kong Chian School of Medicine [Nanyang Technological University] Université de Lausanne = University of Lausanne Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse KTH Royal Institute of Technology [Stockholm] Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Toxicologie Intégrative & Métabolisme
• Publié dans Gut le 25/10/2020

---

Résumé : Objective We evaluated the influence of sex on the pathophysiology of non-alcoholic fatty liver disease (NAFLD). We investigated diet-induced phenotypic responses to define sex-specific regulation between healthy liver and NAFLD to identify influential pathways in different preclinical murine models and their relevance in humans. Design Different models of diet-induced NAFLD (high-fat diet, choline-deficient high-fat diet, Western diet or Western diet supplemented with fructose and glucose in drinking water) were compared with a control diet in male and female mice. We performed metabolic phenotyping, including plasma biochemistry and liver histology, untargeted large-scale approaches (liver metabolome, lipidome and transcriptome), gene expression profiling and network analysis to identify sex-specific pathways in the mouse liver. Results The different diets induced sex-specific responses that illustrated an increased susceptibility to NAFLD in male mice. The most severe lipid accumulation and inflammation/fibrosis occurred in males receiving the high-fat diet and Western diet, respectively. Sex-biased hepatic gene signatures were identified for these different dietary challenges. The peroxisome proliferator-activated receptor α (PPARα) co-expression network was identified as sexually dimorphic, and in vivo experiments in mice demonstrated that hepatocyte PPARα determines a sex-specific response to fasting and treatment with pemafibrate, a selective PPARα agonist. Liver molecular signatures in humans also provided evidence of sexually dimorphic gene expression profiles and the sex-specific co-expression network for PPARα. Conclusions These findings underscore the sex specificity of NAFLD pathophysiology in preclinical studies and identify PPARα as a pivotal, sexually dimorphic, pharmacological target. Trial registration number NCT02390232 .

---

Fichiers liés : Smati et al - 2021 - Integrative study of diet-induced mouse models.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2022
• Auteurs : Thibaut HacquardMarion ClavelPatricia BaldrichEsther LechnerImma Pérez-SalamóMikhail SchepetilnikovBenoît DerrienMarieke DuboisPhilippe HammannLauriane KuhnDanaé BrunNathalie BouteillerNicolas BaumbergerHervé VaucheretBlake MeyersPascal Genschik
• Organismes : Institut de Biologie Moléculaire des Plantes Institut de Biologie Moléculaire des Plantes Donald Danforth Plant Science Center Institut de Biologie Moléculaire des Plantes Institut de Biologie Moléculaire des Plantes Institut de Biologie Moléculaire des Plantes Institut de Biologie Moléculaire des Plantes Institut de Biologie Moléculaire des Plantes Institut de biologie moléculaire et cellulaire Institut de biologie moléculaire et cellulaire Institut de Biologie Moléculaire des Plantes Institut Jean-Pierre Bourgin - Sciences du végétal Institut de Biologie Moléculaire des Plantes Institut Jean-Pierre Bourgin - Sciences du végétal Donald Danforth Plant Science Center Institut de Biologie Moléculaire des Plantes
• Publié dans Cell Reports le 30/10/2020

---

Résumé : RNA silencing is a conserved mechanism in eukaryotes involved in development and defense against viruses. In plants, ARGONAUTE1 (AGO1) protein plays a central role in both microRNA- and small interfering RNA- directed silencing, and its expression is regulated at multiple levels. Here, we report that the F-box protein FBW2 assembles an SCF complex that selectively targets for proteolysis AGO1 when it is unloaded and mutated. Although FBW2 loss of function does not lead to strong growth or developmental defects, it signif- icantly increases RNA-silencing activity. Interestingly, under conditions in which small-RNA accumulation is affected, the failure to degrade AGO1 in fbw2 mutants becomes more deleterious for the plant. Accordingly, the non-degradable AGO1 protein assembles high-molecular-weight complexes and binds illegitimate small RNA, leading to off-target cleavage. Therefore, control of AGO1 homeostasis by FBW2 plays an important role in quality control of RNA silencing.

---

Fichiers liés : 1-s2.0-S2211124722004235-main.pdf

---

Source